FDA Sets Data Formatting Rules for HIV Resistance

Clinical Trials Advisor
The FDA is asking sponsors of antiretroviral drugs to submit clinical trial data sets that include patient, endpoint, genotypic and phenotypic data when reporting on HIV-1 resistance in support of the drug.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00